Does Continuing GLP-1s in Pregnancy Harm the Fetus?

Increasing prescriptions for weight loss drugs have raised major questions about GLP-1 use in pregnancy. Because many pregnancies are unplanned, women frequently expose their fetuses to these medications in early gestation. Consequently, clinicians historically advised immediate discontinuation of these therapies before conception. However, a groundbreaking study now provides essential clinical clarity on this vital topic.

Reassuring Data on GLP-1 Use in Pregnancy

A target trial emulation study analyzed insurance claims from over 3,500 pregnant women. Specifically, researchers compared women who continued their GLP-1 medications into the first trimester against those who stopped. The study assessed severe outcomes such as pregnancy loss, abnormal fetal growth, and major congenital malformations. Importantly, the final results did not show a definitively higher risk for these adverse outcomes among continuers. Nevertheless, some estimates remained statistically imprecise.

Analyzing Key Fetal and Maternal Outcomes

To understand the specific impacts, let us review the exact findings. The risk of a nonlive birth was 29.7% with drug continuation and 27.1% without it. Furthermore, this minor risk difference was not statistically significant. Similarly, the risk of having an infant small or large for gestational age was comparable between groups. Moreover, the prevalence of major congenital malformations did not show a clear increase. Therefore, these findings suggest that accidental exposure may not be as harmful as previously feared. However, physicians must interpret these statistics cautiously due to potential residual confounding from maternal blood sugar control.

Clinical Guidance on GLP-1 Use in Pregnancy

Despite these reassuring findings, current guidelines still recommend stopping GLP-1 receptor agonists before attempting to conceive. Specifically, manufacturers advise a drug clearance period of at least two months before pregnancy. This conservative approach is because animal studies previously demonstrated potential risks like fetal growth restriction. Additionally, poorly controlled maternal diabetes and obesity carry their own significant maternal-fetal risks. Consequently, doctors in India must carefully balance the benefits of glycemic control against the risks of drug exposure. If a patient inadvertently conceives while taking a GLP-1 agonist, these new data offer significant reassurance. Ultimately, shared decision-making is essential to safely guide these high-risk pregnancies.

Frequently Asked Questions

Q1: Is it safe to continue GLP-1 receptor agonists during the first trimester?

Recent clinical data are highly reassuring. However, standard guidelines still recommend discontinuing these drugs before conception. This caution is due to small statistical imprecisions in the studies.

Q2: What are the risks of accidental GLP-1 exposure in early pregnancy?

The risk of miscarriage, abnormal fetal growth, or birth defects does not appear significantly higher with early exposure. Consequently, patients who inadvertently take these medications in early pregnancy can find significant reassurance in these findings.

Q3: How long before pregnancy should a woman stop taking a GLP-1 drug?

Most manufacturers recommend stopping GLP-1 receptor agonists at least two months before trying to conceive. Therefore, planning ahead is critical for women of reproductive age who are using these medications for weight loss.

References

1. Brown JP et al. Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes : A Target Trial Emulation Study Using Claims Information. Ann Intern Med. 2026 Jun 09. doi: 10.7326/ANNALS-25-04820. PMID: 42258827.
2. Cesta CE et al. Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy. JAMA Intern Med. 2024;184(2):144-152. doi:10.1001/jamainternmed.2023.6663.
3. Pondugula N et al. Gestational weight gain and hypertensive disorders of pregnancy with prepregnancy and early pregnancy glucagon-like peptide-1 receptor agonist exposure. Obstet Gynecol. 2026;147(3):293-302. doi:10.1097/AOG.0000000000005995.